F2 Ventures

4M ANALYTICS is a subsurface-infrastructure geo-data company. We developed a mapping engine for utility and infrastructure construction project life cycle, for the pre planning and planning phase, an early comprehensive, mapping simulation tool before the project handed off to the design builder and constructor. Our technology is powered by deep expertise in applying AI and analytics to satellite and aerial imagery analysis for the civil engineering domain. We provide complete, accurate and up to date subsurface infrastructure maps. Our maps are created remotely using AI, without the need for prior as-built data, anywhere in the world and at unprecedented scale and super low cost.

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.

Justt offers chargeback automation and friendly fraud prevention services designed to minimize merchant revenue loss. The platform is specifically designed for eCommerce businesses, providing hands-free chargeback protection that is particularly suited for Shopify merchants. Justt's solutions leverage artificial intelligence to manage chargebacks effectively, ensuring ongoing optimization of results over time.

Five Sigma is a cloud-native, data-driven Claims Management Solution (CMS) with embedded AI/ML capabilities to allow simple and smart claims processing for the insurance industry. Five Sigma simplifies claims management by adding automated claims processing workflows and using data modeling and AI to provide smart recommendations – improving adjusters’ decision-making and reducing errors. Leading insurance carriers, Insurtech, TPAs and Self-Insured companies use Five Sigma's CMS to modernize their claims operations, reduce claims leakage, enhance compliance, and improve their customer experience.

4M ANALYTICS is a subsurface-infrastructure geo-data company. We developed a mapping engine for utility and infrastructure construction project life cycle, for the pre planning and planning phase, an early comprehensive, mapping simulation tool before the project handed off to the design builder and constructor. Our technology is powered by deep expertise in applying AI and analytics to satellite and aerial imagery analysis for the civil engineering domain. We provide complete, accurate and up to date subsurface infrastructure maps. Our maps are created remotely using AI, without the need for prior as-built data, anywhere in the world and at unprecedented scale and super low cost.

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way they treat disease. The company's proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. Orna Therapeutics was established in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts.

Cullinan Pearl develops an orally available tyrosine kinase inhibitor to target Epidermal Growth Factor Receptor exon 20 mutations. Cullinan Pearl is a subsidiary of Cullinan Oncology.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.

TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, improve site selection and planning, and bring new therapies to market faster. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. The TriNetX platform is HIPAA and GDPR compliant.

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.

Cullinan Pearl develops an orally available tyrosine kinase inhibitor to target Epidermal Growth Factor Receptor exon 20 mutations. Cullinan Pearl is a subsidiary of Cullinan Oncology.

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.

IPrice was set up to offer shoppers the widest selection of products and brands, provided by hundreds of partners in Southeast Asia. The company is driven by a mission to bring a greater level of transparency, convenience, and trust to the e-commerce market in Southeast Asia by making it easy for shoppers to compare prices, discover products, and get the best deals from thousands of online shops. With the help and funding of the Asia Venture Group—investments include iMoney, Trusted Company, and Happy Fresh—iPrice quickly acquired international know-how, expertise, and talent in fields ranging from technology to online marketing to the business side of things. Focused on execution from its headquarters in Kuala Lumpur, the company has quickly expanded across seven markets, including Indonesia, Vietnam, Singapore, Hong Kong, Thailand, and the Philippines.

Clinical Ink, Inc. provides eSource solutions for the clinical trials industry. It offers SureSource, an electronic source solution that allows users to record comments, explanations, and validated source data on protocol-specific eSource documents, as well as captures the data required by the protocol. The company also provides an electronic source record (ESR) for clinical trials that provides cleaner data. In addition, it offers hosting services. Clinical Ink was founded in 2006 and is based in Winston-Salem, North Carolina.

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

Developer of proprietary blood-based biomarker tests to transform the management of chronic respiratory diseases. The company is focused on addressing the unmet need for tools to provide a real-time, biological assessment of a patient’s disease state. ProterixBio's products will enable health care providers to better manage their patients and avoid unnecessary hospitalizations, leading to improved outcomes and reduced health care costs. It was founded in 2002 and headquartered in Billerica, Massachusetts.

Developer of proprietary blood-based biomarker tests to transform the management of chronic respiratory diseases. The company is focused on addressing the unmet need for tools to provide a real-time, biological assessment of a patient’s disease state. ProterixBio's products will enable health care providers to better manage their patients and avoid unnecessary hospitalizations, leading to improved outcomes and reduced health care costs. It was founded in 2002 and headquartered in Billerica, Massachusetts.

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

Developer of proprietary blood-based biomarker tests to transform the management of chronic respiratory diseases. The company is focused on addressing the unmet need for tools to provide a real-time, biological assessment of a patient’s disease state. ProterixBio's products will enable health care providers to better manage their patients and avoid unnecessary hospitalizations, leading to improved outcomes and reduced health care costs. It was founded in 2002 and headquartered in Billerica, Massachusetts.